Results 161 to 170 of about 286,222 (357)
Advanced Science, EarlyView.In this work, we showcased two significant scientific advances in (i) developing a portable biosensor technology for rapid decentralized prostate cancer urinary biomarker testing and reporting, with superior performance to current clinical testing practice; and (ii) proposing a clinical validation framework (for our biosensor development) which can be ...
Kevin M. Koo +14 more
wiley +1 more source
Adults with blood cancers respond to booster, not initial dose of COVID-19 vaccine.
, 2022 openalex +1 more source
Cancer Vaccines: A Ray of Hope [PDF]
, 2014 In lieu of an abstract, here are the article\u27s first two paragraphs: Recent cancer statistics review by Surveillance, Epidemiology, and End Results (SEER) Program by National Cancer Institute (NCI) shows that cancer is the second most leading cause of
Chablani, Lipika
core +1 more source
Advanced Science, EarlyView.Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source
Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding [PDF]
, 2008 Sjoerd H. van der Burg
openalex +1 more source
Advanced Science, EarlyView.Hyaluronic acid‐modified bimetallic peroxide nanocomposites (MgO2‐CuO2@HA) are designed for synergistic tumor therapy. The nanocomposites release Mg2+, H2O2, and Cu2+ in tumor cells, induce cuproptosis via Cu+‐mediated protein aggregation, and activate pyroptosis through caspase‐1/gasdermin D pathways for inducing immunogenic cell death, collectively ...
Guanting He +8 more
wiley +1 more source
Intestinal microbiota modulates the anti-tumor effect of oncolytic virus vaccine in colorectal cancer [PDF]
, 2023 Xia Chen +4 more
openalex +1 more source
A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines
Advanced Science, EarlyView.OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin +4 more
wiley +1 more source
141 PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants [PDF]
, 2020 Matthew G. Booty +12 more
openalex +1 more source